Yet another European country has stepped forward with a drug-budgeting strategy--only this time, it doesn't include price cuts. Italy's health minister is promising to save money through broader use
Drugmakers have lost the fight to stave off new generic-switching incentives in the U.K. The European Court of Justice ruled that, contrary to the pharma industry's claims, the incentive plan doesn't
It's a pitched battle over Prograf. Fast-moving, too: FDA rejected Astellas Pharma's petition for tougher-than-normal approval standards for copycat forms of its transplant drug. Novartis got the FDA
Wal-Mart slashed its employee drug benefits in half, cutting the number of branded meds on its formulary to 128 from 260, BNet Pharma reports. Big-time drugs like Sanofi-Aventis' Ambien CR and
When does a cost-cutting incentive no longer cut costs? Here's an example, as reported by the Wall Street Journal: Drug co-pays could lose their effectiveness as a way to steer patients to lower-cost
According to a new review of randomized controlled trials, editorials and commentaries published in today's issue of the Journal of the American Medical Association (JAMA), patients who spend extra
Big Pharma may have found some unexpected allies in its battle against generic competition: consumer groups. Two advocacy organizations in Florida are warning consumers about "therapeutic switching,"